Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women

[1]  P. Williams,et al.  HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses ‐ a prospective comparison in the pre‐operative evaluation of pelvic masses in an Australian population , 2015, The Australian & New Zealand journal of obstetrics & gynaecology.

[2]  Joong-Sub Choi,et al.  Feasibility and efficacy of laparoscopic restaging surgery for women with unexpected ovarian malignancy. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[3]  Hong-yan Cheng,et al.  Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[4]  T. Aw,et al.  Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings , 2015, Journal of gynecologic oncology.

[5]  M. Panteghini,et al.  The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer , 2014, Clinical chemistry and laboratory medicine.

[6]  F. Ghezzi,et al.  Laparoscopic and Open Abdominal Staging for Early-Stage Ovarian Cancer: Our Experience, Systematic Review, and Meta-analysis of Comparative Studies , 2014, International Journal of Gynecologic Cancer.

[7]  M. I. da Rosa,et al.  Accuracy of Serum Human Epididymis Protein 4 in Ovarian Cancer Diagnosis: A Systematic Review and Meta-Analysis , 2014, International Journal of Gynecologic Cancer.

[8]  L. Bian,et al.  Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. , 2014, Molecular and clinical oncology.

[9]  L. Frati,et al.  Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. , 2013, Oncology reports.

[10]  S. Tomao,et al.  Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach , 2013, Journal of experimental & clinical cancer research : CR.

[11]  J. Qin,et al.  Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[12]  M. Panteghini,et al.  Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review , 2013, Journal of Clinical Pathology.

[13]  Massimo Candiani,et al.  Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. , 2013, Gynecologic oncology.

[14]  D. Hashad,et al.  Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? , 2013, Archives of Gynecology and Obstetrics.

[15]  Jie He,et al.  Report of incidence and mortality in China cancer registries, 2009. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[16]  M. Thevarajah,et al.  Human epididymis protein 4 reference intervals in a multiethnic asian women population. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[17]  Jie He,et al.  Report of incidence and mortality in China Cancer Registries, 2008 , 2012, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[18]  R. Angioli,et al.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer? , 2012, Tumor Biology.

[19]  Richard G. Moore,et al.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. , 2012, American journal of obstetrics and gynecology.

[20]  Sanjiv S Gambhir,et al.  Early diagnosis of ovarian carcinoma: is a solution in sight? , 2011, Radiology.

[21]  F. Ghezzi,et al.  Laparoscopy Staging of Early Ovarian Cancer: Our Experience and Review of the Literature , 2009, International Journal of Gynecologic Cancer.

[22]  Patrick O. Brown,et al.  The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection , 2009, PLoS medicine.

[23]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[24]  G. Cornwall,et al.  Extracellular quality control in the epididymis. , 2007, Asian journal of andrology.

[25]  F. Ghezzi,et al.  Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. , 2007, Gynecologic oncology.

[26]  C. Muller,et al.  Incidence and Survival Rates for Female Malignant Germ Cell Tumors , 2006, Obstetrics and gynecology.

[27]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[28]  Roger E Bumgarner,et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.

[29]  M. Panteghini,et al.  Human epididymis protein 4: factors of variation. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[30]  M. Speeckaert,et al.  Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. , 2013, Advances in clinical chemistry.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[32]  Richard G. Moore,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.